Excedrin (brand)

It was manufactured by Bristol-Myers Squibb until it was purchased by Novartis in July 2005 along with other products from BMS's over-the-counter business.

As of March 2015, GSK holds majority ownership of Excedrin through a joint venture transaction with Novartis.

In 2007, the brand branched out into marketing for other types of pains with the introduction of Excedrin Back & Body, without caffeine.

The reason was that the combination of acetaminophen with aspirin creates the risk of renal papillary necrosis if large doses are taken chronically.

In 2005, Bristol-Myers Squibb announced the sale of its North American consumer medicine business (including Excedrin, Comtrex and Keri brands) to Novartis for $660 million, in order to focus on drugs for the ten most profitable disease areas.

[17] On December 26, 2020, the U.S. Consumer Product Safety Commission announced the recall of 400,000 bottles of Excedrin due to the containers of the drug allegedly having holes in the bottom.

The concern behind the recall was that the plastic bottles, if they had a hole, could allow children to access the painkiller caplets and lead to dangerous overdose or poisoning.